LLY Jul 2024 450.000 put
- PR Newswire
Lilly Announces Details of Presentations at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Verzenio® (abemaciclib; a CDK4/6 inhibitor), Retevmo® (selpercatinib; a rearranged during transfection [RET] inhibitor), olomorasib (an investigational KRAS G12C inhibitor) and imlunestrant (an investigational oral selective estrogen receptor degrader [SERD]) will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 – June 4 in Chicago.
- Insider Monkey
Is Eli Lilly and Company the Largest Publicly Traded Healthcare Company?
In this article, we will be taking a look at is Eli Lilly and Company the largest publicly traded healthcare company? If you wish to learn about more companies, head straight to the Top 20 Largest Publicly Traded Healthcare Companies. Major Players Driving the U.S. Healthcare Industry’s Growth and Innovation The global healthcare industry is […]
- Barrons.com
Hims & Hers Is Selling Copycat Weight-Loss Drugs. Here’s How.
A plan by Hims & Hers Health to sell legal copies of Novo Nordisk weight loss drug Wegovy is drawing pushback from the industry, and bringing new attention to an area of concern for public-health officials. Enormous demand has created shortages of Novo’s Wegovy, as well as a competing weight loss injection from Eli Lilly called Zepbound. Both companies are spending billions of dollars to increase their manufacturing capacity, but the availability of the medicines is limited in the U.S., according to the Food and Drug Administration.
